Correlation between Topo IIα expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas

Anticancer Research

Volumn 21, Issue 2 A, 2001, Pages 905-910

  Koshiyama, M ^a   Fujii, H ^a   Kinezaki, M ^a   Yoshida, M ^a  

^a OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

Cisplatin; Cyclophosphamide; Doxorubicin; Endometrial carcinoma; Etoposide; MTT assay; Ovarian carcinoma; Topoisomerase II

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOFOS; TETRAZOLIUM;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; ENDOMETRIUM CARCINOMA; FEMALE; FEMALE GENITAL TRACT TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; ETOPOSIDE; FEMALE; HUMANS; ISOENZYMES; OVARIAN NEOPLASMS;

EID: 0035009052     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Cleavage of DNA by mammalian DNA topoisomerase II
2. Structure and mechanism of DNA topoisomerase II
3. DNA topoisomerase poisons as antitumour drugs
4. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II
5. Proliferation- and cell cycle-dependent differences in the expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells
6. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: A gynaecological oncology group study
7. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide
8. Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide
9. Chemotherapy of ovarian cancer
10. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma
11. Immunohistochemical staining of DNA topoisomerase II in frozen and formalin-fixed paraffin-embedded human tissues
12. Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man
13. Chemosensitivity testing of irinotecan (CPT-11) in ovarian and endometrial carcinomas: A comparison with cisplatin
14. MTT assay with reference to the clinic effect of chemotherapy
15. Further evidence for the value of the chemosensitivity test in deciding appropriate chemotherapy for advanced gastric cancer
16. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II
17. Gene expression of DNA topoisomerase I, IIα and β and response to cisplatin-based chemotherapy in advanced ovarian carcinoma
18. High rate of expression of multidrug resistance-associated P-glycoprotein in human endometrial carcinoma normal endometrial tissue